Raphael Pharmaceutical Inc

Raphael Pharmaceutical Inc has a negative equity position of -$103,000,000, indicating a significant deficit in its capital structure. The company holds $287,000,000 in cash and equivalents, which is partially offset by total liabilities of $456,000,000. The current ratio of 0.77 suggests that the company's current assets are insufficient to cover its current liabilities, raising concerns about short-term liquidity. The company's liquidity risk is assessed as low, but the negative equity position and operating losses indicate a need for continued capital infusions.

The company reported a net loss of $550,000,000 and an operating loss of $547,000,000, with a return on assets of -1.56%. These figures are below the industry median for profitability metrics, indicating that Raphael Pharmaceutical Inc is underperforming relative to its peers in terms of asset utilization and profitability. The return on equity of 5.34% is also below the industry median, suggesting that the company is not generating strong returns for its shareholders.

Raphael Pharmaceutical Inc does not disclose segment or geographic revenue data in its latest financials, making it difficult to assess the concentration of its revenue streams. The absence of such data limits the ability to evaluate the company's exposure to specific markets or product lines.

The company's growth trajectory is constrained by its current financial position. With no disclosed revenue history and a negative operating cash flow of -$172,000,000, Raphael Pharmaceutical Inc is not generating positive cash flow from operations. The company's capital expenditures are minimal at -$1,000,000, indicating a lack of investment in long-term growth initiatives.

The risk assessment indicates that the company has low dilution risk, with no immediate filing-based liquidity or dilution flags detected. However, the negative equity position and reliance on cash reserves suggest that the company may need to raise additional capital in the future, which could lead to share dilution. The company's long-term debt is relatively low at $37,000,000, but the overall capital structure is weak, with a debt-to-equity ratio of -0.36.

There are no recent events or filings disclosed in the latest financial data that would indicate significant changes in the company's operations or strategic direction. The absence of recent events or transcripts limits the ability to assess the company's current performance and future outlook.